Risk factors
Instil Bio (TIL) risk factors
Item 1A of every Instil Bio, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors74 risks16 new23 dropped30 reworded
Instil Bio shifted from clinical-stage oncology to an acquirer of early-stage assets after discontinuing multiple programs and workforce reductions.
Filed Mar 27, 2026 - FY2024 10-K risk factors81 risks
Instil Bio faces high financial losses, having accumulated $655.1 million in deficit as of December 31, 2024. The company relies heavily on its collaboration with ImmuneOnco for its lead product candidates AXN-2510/IMM2510 and AXN-27M/IMM27M. It has zero commercial products and no history of completing clinical trials.
Filed Mar 04, 2025